FUJI CORP./ JP3809200003 /
2024-05-13 10:30:01 AM | Chg. -0.7000 | Volume | Bid10:30:01 AM | Ask10:30:01 AM | High | Low |
---|---|---|---|---|---|---|
15.5000EUR | -4.32% | 0 Turnover: 0.0000 |
15.5000Bid Size: 140 | 16.4000Ask Size: 130 | 15.5000 | 15.5000 |
GlobeNewswire
2:00 PM
Alvotech Announces Webcast of First Quarter 2024 Financial Results on May 22, 2024, at 8:00 am EDT (...
GlobeNewswire
04-30
U.S. Commercialization Agreement with Quallent to Drive Patient Savings with First High-Concentratio...
GlobeNewswire
04-24
Alvotech Announces Topline Results from a Confirmatory Clinical Study for AVT05, a Proposed Biosimil...
GlobeNewswire
04-19
Alvotech signs U.S. agreement to expand access for newly approved high-concentration interchangeable...
GlobeNewswire
04-16
Alvotech and Teva Announce U.S. FDA Approval of SELARSDI™ (ustekinumab-aekn), biosimilar to Stelara®...
GlobeNewswire
04-15
Blue World Acquisition Corporation Postponed the Extraordinary General Meeting to Approve the Busin...
GlobeNewswire
04-03
Blue World Acquisition Corporation Announces Extension of the Deadline for an Initial Business Combi...
GlobeNewswire
03-20
Alvotech Reports Financial Results for Full Year 2023 and Provides a Business Update
GlobeNewswire
03-14
Century Therapeutics Reports Full Year 2023 Financial Results and Provides Business Updates
GlobeNewswire
03-05
Alvotech Announces Webcast of Full Year 2023 Financial Results on March 21, 2024, at 8:00 am ET
GlobeNewswire
02-26
Alvotech Accepts Offer for the Sale of Shares for a value of approximately USD 166 million at a Purc...
GlobeNewswire
02-24
Alvotech and Teva Announce U.S. Approval of SIMLANDI® (adalimumab-ryvk) injection, the first interc...
GlobeNewswire
02-15
Alvotech Announces Expected Global Market Entry Dates for AVT04 Biosimilar to Stelara® (ustekinumab)
GlobeNewswire
02-06
Blue World Acquisition Corporation Announces Extension of the Deadline for an Initial Business Combi...